8-K: GlycoMimetics Stockholders Greenlight Merger with Crescent Biopharma, Approve 1-for-100 Reverse Stock Split

GlycoMimetics, Inc. stockholders have overwhelmingly approved the proposed merger with Crescent Biopharma, Inc., along with a significant 1-for-100 reverse stock split and other key proposals, paving the way for the combined entity to trade as Crescent Biopharma, Inc. under the new ticker CBIO.

Summary

• GlycoMimetics, Inc. stockholders approved the proposed merger with Crescent Biopharma, Inc. and all related proposals at a special meeting on June 5, 2025.
• The GlycoMimetics Board of Directors subsequently approved a 1-for-100 reverse stock split of its common stock.
• The reverse stock split is expected to reduce GlycoMimetics' outstanding common stock from approximately 64.5 million shares to approximately 0.6 million shares.
• Following the merger, the combined company, to be named Crescent Biopharma, Inc., is expected to commence trading on Nasdaq under the ticker symbol CBIO on June 16, 2025.
• Stockholders also approved an increase in authorized common stock from 150,000,000 to 175,000,000 shares.
• Approval was also granted for the redomestication of GlycoMimetics from Delaware to the Cayman Islands.
• The combined company's total issued and outstanding common stock is expected to be approximately 14.8 million shares, or 25.3 million shares on a fully-diluted basis, post-merger and reverse split.
• All ten proposals presented to stockholders, including the Nasdaq Stock Issuance Proposal, Authorized Share Increase Proposal, Reverse Stock Split Proposal, and Redomestication Proposal, received requisite approval.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as all key proposals for the merger and strategic restructuring were approved by stockholders, and the board has taken definitive steps (like approving the reverse stock split) to move forward. This indicates successful execution of a major corporate transaction, which is generally viewed favorably, despite inherent risks in forward-looking statements.

Positives

• Stockholders overwhelmingly approved the merger with Crescent Biopharma, indicating strong support for the strategic direction.
• The approval of the 1-for-100 reverse stock split is a positive step to meet Nasdaq listing requirements and potentially increase per-share price, enhancing market appeal.
• The increase in authorized shares provides flexibility for future capital raises or strategic transactions for the combined company.
• Approval of the Crescent Biopharma, Inc. 2025 Stock Incentive Plan and Employee Stock Purchase Plan will enable the combined company to attract and retain talent.
• The redomestication to the Cayman Islands may offer corporate governance or tax advantages, subject to further analysis.

Risks

• Risk that conditions to the closing or consummation of the Proposed Transactions are not satisfied.
• Risk that the proposed pre-closing financing is not completed in a timely manner or at all.
• Uncertainties regarding the timing of the consummation of the Proposed Transactions.
• Risks related to GlycoMimetics' continued listing on Nasdaq until closing and the combined company's ability to remain listed post-merger.
• Risks related to GlycoMimetics' and Crescent's ability to correctly estimate operating expenses and merger-associated expenses.
• Uncertainties regarding the impact any delay in closing would have on the anticipated cash resources of the combined company.
• Failure or delay in obtaining required approvals from governmental or quasi-governmental entities.
• Occurrence of any event, change, or condition that could give rise to the termination of the business combination.
• Costs related to the Merger.
• Risk that, as a result of adjustments to the exchange ratio, Crescent stockholders and GlycoMimetics stockholders could own more or less of the combined company than currently anticipated.
• Outcome of any legal proceedings that may be instituted against GlycoMimetics, Crescent, or their directors/officers related to the Merger Agreement.
• Unexpected costs, charges, or expenses resulting from the Proposed Transactions.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Proposed Transactions.
• General risks associated with companies operating in the biopharma industry.

Future Outlook

The combined company, Crescent Biopharma, Inc., is expected to commence trading on Nasdaq under the ticker symbol CBIO on June 16, 2025, following the reverse stock split and merger consummation. The company anticipates having approximately 14.8 million shares outstanding (25.3 million fully-diluted) post-merger. The focus will shift to advancing Crescent's pipeline of precision-engineered molecules for solid tumors, including CR-001, a tetravalent PD-1 x VEGF bispecific antibody, and antibody drug conjugates CR-002 and CR-003.

Management Comments

• GlycoMimetics, Inc. today announced that its stockholders have approved the proposed merger with Crescent Biopharma, Inc. and all related proposals.
• On June 5, 2025, following the Special Meeting, the Board approved a reverse stock split of GlycoMimetics common stock at a ratio of 1-for-100.

Industry Context

This merger represents a strategic pivot for GlycoMimetics, a late clinical-stage biotechnology company previously focused on glycobiology-based therapies, into the solid tumor oncology space through its combination with Crescent Biopharma. Such mergers are common in the biotechnology industry, especially for companies seeking to revitalize their pipeline, gain access to new therapeutic areas, or achieve a stronger financial footing and market presence. The move allows GlycoMimetics to leverage its public listing for Crescent's pipeline, which includes bispecific antibodies and antibody-drug conjugates, a highly active and competitive area in oncology drug development.

Comparison to Industry Standards

• The 1-for-100 reverse stock split is a common corporate action for companies whose stock price has fallen below Nasdaq's minimum bid price requirement, aiming to regain compliance and improve market perception. For example, similar reverse splits have been undertaken by other biotech companies like Sorrento Therapeutics (1-for-10) or Athersys (1-for-25) to maintain listing.
• The merger with Crescent Biopharma, a company with a pipeline focused on solid tumors, aligns with a broader industry trend of consolidation and strategic partnerships, particularly in the oncology sector. Many larger pharmaceutical companies and established biotechs acquire smaller, innovative firms to expand their therapeutic portfolios, similar to recent acquisitions like Merck's acquisition of Prometheus Biosciences for its immunology pipeline or Pfizer's acquisition of Seagen for its ADC technology.
• The approval of new stock incentive and employee stock purchase plans is standard practice for combined entities to align employee incentives with shareholder value and attract talent, comparable to compensation structures seen across the biotech industry.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions 'the outcome of any legal proceedings that may be instituted against GlycoMimetics, Crescent or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby' as a risk factor, indicating potential for litigation related to the merger.

Stakeholder Impact

• **Shareholders**: GlycoMimetics shareholders will become shareholders of the combined company (Crescent Biopharma, Inc.) and will experience a 1-for-100 reverse stock split, significantly reducing their share count but proportionally increasing their per-share value. Fractional shares will be cashed out. Their ownership percentage in the combined company will be determined by the exchange ratio.
• **Employees**: The approval of the Crescent Biopharma, Inc. 2025 Stock Incentive Plan and Employee Stock Purchase Plan indicates that employees of the combined entity will have opportunities for equity participation and incentives.
• **Management**: Compensation arrangements for GlycoMimetics named executive officers related to the merger were approved on an advisory basis, indicating potential benefits for current management. The board composition will be reconstituted post-merger.
• **Customers/Partners**: The merger signifies a strategic shift in the company's therapeutic focus from glycobiology to solid tumors, potentially impacting existing partnerships or customer relationships related to GlycoMimetics' prior pipeline, while opening new opportunities for Crescent's programs.

Next Steps

• GlycoMimetics will file a certificate of amendment to its charter with the Secretary of State of Delaware to effect the Reverse Stock Split.
• The Reverse Stock Split is expected to become effective prior to the closing of the Merger.
• Consummation of the Merger is anticipated.
• The combined company's common stock is expected to commence trading on a split-adjusted, post-Merger basis on Nasdaq under the name Crescent Biopharma, Inc. and ticker symbol CBIO at the open of trading on June 16, 2025.
• PricewaterhouseCoopers LLP is expected to be appointed as the Combined Company's independent registered public accounting firm for fiscal year ending December 31, 2025, if the Merger is completed.

Key Dates

Recommendation

Keywords

Merger, Reverse Stock Split, Biopharma, GlycoMimetics, Crescent Biopharma, Nasdaq Listing, Stockholder Approval, Corporate Action, Biotechnology, SEC Filing